{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.6","value":"3.3"},{"groupId":"OG001","spread":"10.5","value":"3.6"},{"groupId":"OG002","spread":"11.0","value":"3.3"}]}],"title":"Week 12, MCS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.5","value":"2.7"},{"groupId":"OG001","spread":"10.4","value":"3.0"},{"groupId":"OG002","spread":"11.3","value":"3.3"}]}],"title":"Week 24, MCS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.3","value":"4.1"},{"groupId":"OG001","spread":"8.5","value":"7.7"},{"groupId":"OG002","spread":"8.3","value":"7.0"}]}],"title":"Week 12, PCS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.0","value":"4.9"},{"groupId":"OG001","spread":"9.0","value":"8.5"},{"groupId":"OG002","spread":"9.0","value":"8.6"}]}],"title":"Week 24, PCS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"229"},{"groupId":"OG002","value":"219"}],"units":"Participants"}],"description":"The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \\[MCS\\] and physical \\[PCS\\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo administered orally (PO) once daily (QD) through Week 24.\n\nParticipants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg PO QD through week 24.\n\nParticipants will continue to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg PO QD through week 24.\n\nStarting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally daily through Week 24.\n\nParticipants will continue to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"MEAN","populationDescription":"mITT population: all randomized participants who received at least 1 dose of the study drug , with a baseline value and at least 1 post-baseline value. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using mLOCF.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12; Baseline, Week 24","title":"Change From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)","type":"SECONDARY","unitOfMeasure":"units on a scale"}